Hyoscine butylbromide
No structure available
Hyoscine butylbromide could not be matched to a single known compound.
Background
Listing
- Schedules
- Schedule 1 to 3, conditions apply
- Source
- Consolidated Schedules 06 July 2026
Registered medicines
1 registered product listed
Counted through the register's ingredient index, which does not reach every record.
| Name | Brands | Dosages | Applicants | Registrations | Schedule |
|---|---|---|---|---|---|
| Hyoscine butylbromide | Butyronex, Juposci | 5 mg, 20 | 2 applicants | 2 registrations | S1 |
Regulatory status
Where S1 to S3 sits on the scale
Depends on which listing applies
At the least restrictive, Schedule 1: sold by a pharmacist, no doctor's prescription needed. At the most restrictive, Schedule 3: needs a doctor's prescription, dispensed by a pharmacist. The listings below say which applies to which form, strength or pack size.
Schedule S1 to S3, as the Consolidated Schedules list it.
Who may supply: A pharmacist dispensing against a written or verbal prescription from an authorised prescriber; a veterinarian, who may also prescribe, compound or dispense it directly; a medical practitioner or dentist, who may prescribe it and may compound or dispense it directly only if licensed under section 22C(1)(a); manufacturers and wholesalers may supply people who may lawfully possess it; and, for animal treatment, a person practising a para-veterinary profession, on a veterinarian's written or verbal instruction.
Consolidated Schedules listings for Hyoscine butylbromide
S3: Hyoscine butylbromide
- substances, preparations and mixtures thereof-
- except when intended for oral administration; (S1, S2) and
- except transdermal preparations when intended for the prevention of the symptoms of motion sickness. (S2)
Consolidated Schedules 06 July 2026, lines 3727 to 3732
S2: Hyoscine butylbromide
- substances, preparations and mixtures thereof-
- when intended for oral administration in pack sizes exceeding 20 tablets or 100 ml, or strengths exceeding 10 mg per oral solid dosage form or 0.1% mass/ volume; (S1)
- transdermal preparations when intended for the prevention of the symptoms of motion sickness; (S3)
- except when intended for parenteral administration. (S3)
Consolidated Schedules 06 July 2026, lines 2119 to 2124
S1: Hyoscine butylbromide
- substances, preparations and mixtures thereof-
- when intended for oral administration in pack sizes not exceeding 20 tablets of 10 mg strength or less, or 100 ml of oral liquid dosage of 0.1% mass/ volume or less; (S2)
- except transdermal preparations when intended for the prevention of the symptoms of motion sickness; (S2)
- except when intended for parenteral administration. (S3)
Consolidated Schedules 06 July 2026, lines 523 to 529
This is an informational summary of the Medicines and Related Substances Act 101 of 1965 and its 2017 General Regulations. It is not medical advice and not legal advice. Always check the medicine's label, which carries the schedule number inside a square border, or ask a pharmacist if you are unsure.